期刊
METABOLIC BRAIN DISEASE
卷 36, 期 7, 页码 1641-1671出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-021-00788-3
关键词
Metabolome; Metabolite; Autism; Diagnostic marker; Therapeutic marker; Intervention
资金
- National Research Council of Thailand
- Thailand Science Research and Innovation [MRG6280014]
- NSTDA Research Chair grant from the National Science and Technology Development Agency Thailand
- Chiang Mai University Center of Excellence Award Thailand
- National Institute of General Medical Sciences of the National Institutes of Health [P20GM125503]
Early diagnosis and treatment of autism spectrum disorder (ASD) are challenging, and further research is needed. Metabolomics is a promising tool for identifying potential biomarkers and possible pathogenesis of ASD, providing new insights for future treatments.
Early diagnosis and treatment for autism spectrum disorder (ASD) pose challenges. The current diagnostic approach for ASD is mainly clinical assessment of patient behaviors. Biomarkers-based identification of ASD would be useful for pediatricians. Currently, there is no specific treatment for ASD, and evidence for the efficacy of alternative treatments remains inconclusive. The prevalence of ASD is increasing, and it is becoming more urgent to find the pathogenesis of such disorder. Metabolomic studies have been used to deeply investigate the alteration of metabolic pathways, including those associated with ASD. Metabolomics is a promising tool for identifying potential biomarkers and possible pathogenesis of ASD. This review comprehensively summarizes and discusses the abnormal metabolic pathways in ASD children, as indicated by evidence from metabolomic studies in urine and blood. In addition, the targeted interventions that could correct the metabolomic profiles relating to the improvement of autistic behaviors in affected animals and humans have been included. The results revealed that the possible underlying pathophysiology of ASD were alterations of amino acids, reactive oxidative stress, neurotransmitters, and microbiota-gut-brain axis. The potential common pathways shared by animal and human studies related to the improvement of ASD symptoms after pharmacological interventions were mammalian-microbial co-metabolite, purine metabolism, and fatty acid oxidation. The content of this review may contribute to novel biomarkers for the early diagnosis of ASD and possible therapeutic paradigms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据